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Abstract
Background: The aim of this trial is to evaluate the effect of SENATOR software on incident, adverse drug reactions
(ADRs) in older, multimorbid, hospitalized patients. The SENATOR software produces a report designed to optimize
older patients’ current prescriptions by applying the published STOPP and START criteria, highlighting drug-drug
and drug-disease interactions and providing non-pharmacological recommendations aimed at reducing the risk of
incident delirium.
(Continued on next page)
* Correspondence: j.eustace@ucc.ie
3Health Research Board Clinical Research Facility-Cork, University College
Cork, Cork University Hospital, Wilton, Cork, IrelandT12 DC4A
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lavan et al. BMC Geriatrics           (2019) 19:40 
https://doi.org/10.1186/s12877-019-1047-9
(Continued from previous page)
Methods: We will conduct a multinational, pragmatic, parallel arm Prospective Randomized Open-label, Blinded
Endpoint (PROBE) controlled trial. Patients with acute illnesses are screened for recruitment within 48 h of arrival to
hospital and enrolled if they meet the relevant entry criteria. Participants’ medical history, current prescriptions,
select laboratory tests, electrocardiogram, cognitive status and functional status are collected and entered into a
dedicated trial database. Patients are individually randomized with equal allocation ratio. Randomization is stratified
by site and medical versus surgical admission, and uses random block sizes. Patients randomized to either arm
receive standard routine pharmaceutical clinical care as it exists in each site. Additionally, in the intervention arm an
individualized SENATOR-generated medication advice report based on the participant’s clinical and medication data
is placed in their medical record and a senior medical staff member is requested to review it and adopt any of its
recommendations that they judge appropriate. The trial’s primary outcome is the proportion of patients experiencing
at least one adjudicated probable or certain, non-trivial ADR, during the index hospitalization, assessed at 14 days post-
randomization or at index hospital discharge if it occurs earlier. Potential ADRs are identified retrospectively by the site
researchers who complete a Potential Endpoint Form (one per type of event) that is adjudicated by a blinded, expert
committee. All occurrences of 12 pre-specified events, which represent the majority of ADRs, are reported to the
committee along with other suspected ADRs. Participants are followed up 12 (+/− 4) weeks post-index hospital
discharge to assess medication quality and healthcare utilization.
This is the first clinical trial to examine the effectiveness of a software intervention on incident ADRs and associated
healthcare costs during hospitalization in older people with multi-morbidity and polypharmacy.
Trial registration number: Clinicaltrials.gov NCT02097654, 27 March 2014.
Keywords: Adverse drug reactions, Randomized controlled trial, Older adults, Hospitalization, Computer software,
Intervention study, Medication alert systems, Polypharmacy, Multimorbidity
Background
Adverse drug reactions (ADRs) represent a significant and
growing global healthcare problem, especially in the elderly
population. ADRs may both cause hospitalization, and/or
occur in hospital. Approximately 11% of hospital admissions
in adults aged ≥65 years are caused by ADRs [1], while one
in ten hospitalised patients are reported to experience an
ADR during their inpatient stay [2]. Older age [2], female
gender [3], multi-morbidity [4], polypharmacy [4] and frailty
[5] are significant predictors of ADRs and are central to the
GerontoNet ADR prediction tool described in 2010 [6].
Since approximately half of all ADRs are thought to be pre-
ventable [7], they represent a major, modifiable contributor
to morbidity and mortality in older subjects.
Inappropriate prescribing and excessive polypharmacy
are both linked to ADRs, but few interventions addressing
these risks have been evaluated. A recent single centre clin-
ical trial showed that the application of the ‘Screening Tool
of Older Persons’ Prescriptions’ (STOPP) and ‘Screening
Tool to Alert doctors to the Right Treatment’ (START)
screening tools by an experienced geriatrician within 48 h
of admission reduced incident in-hospital ADRs from 21.0
to 11.7% [8]. Patients recruited to this study were adults 65
years and older admitted acutely to hospital; patients were
excluded if they were admitted directly to the intensive care
unit, under geriatric medicine, old age psychiatry, clinical
pharmacology or palliative medicine. Additional studies
have shown that the manual (i.e. not delivered by software)
application of STOPP/START criteria improves medication
appropriateness [9, 10] and reduces the risk of falls [11].
However, these trials have been single centre and un-
blinded. Furthermore, the lack of sufficient geriatric medi-
cine specialists limits the applicability of this manual
approach. To overcome these limitations, a novel software
tool called SENATOR (Software ENgine for the Assessment
and optimisation of drug and non-drug Therapy in Older
peRsons) was developed, which automatically provides indi-
vidualized STOPP/START and other relevant recommen-
dations based on standardized inputs. Given the support in
the literature for the efficacy of the STOPP/START recom-
mendations, we decided to conduct a pragmatic trial to
quantify the effectiveness of providing the individualised
SENATOR software report to the participating patient’s at-
tending hospital clinician for review and implementation as
he/she judges appropriate compared to usual clinical care,
with the aim of reducing in-hospital ADRs amongst older
adults in a real world setting across 6 European hospitals.
Methods
The SENATOR Trial is a multinational, pragmatic, paral-
lel arm Prospective Randomized Open-label, Blinded End-
point (PROBE) controlled trial [12]. It is pragmatic in
nature, in that it aims to evaluate the SENATOR software
in real world clinical practice with decisions being made
by busy clinicians. The trial is funded by the European
Union Framework Programme 7 and includes a diverse
geographical make-up, with participation of six large
university-affiliated hospitals from across Europe (Ireland,
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Scotland, Iceland, Spain, Italy and Belgium). The trial is
registered with clinicaltrials.gov (NCT02097654).
Entry criteria
To be eligible for inclusion, participants have to be 65
years or older and must be admitted to a hospital in a
non-elective manner, under the care of a medical or sur-
gical service, and have an initial management plan in
place (Table 1). Subjects are required to have 3 or more
active co-morbidities, defined as conditions requiring
ongoing medical therapy. Patients are excluded if they
are admitted under the care of specialists in geriatric
medicine or clinical pharmacology, or if they have
already been reviewed by these services or are scheduled
to undergo such a consultation, since these services pro-
vide similar advice to the SENATOR software, poten-
tially supressing the observed ADR event rates and
making it more difficult to detect any benefit from the
intervention. Similarly, patients admitted to intensive
care units or under the care of oncologists, as well as pa-
tients with liver failure, renal failure receiving dialysis,
and patients with solid organ transplants, will also be ex-
cluded, since detailed specialist scrutiny and adjustment
of prescribed medications occur regularly in these
settings. As ADR rates are highest in the initial days
following admission, patients are required to give their
informed consent within 48 h of arrival to hospital and
be randomized within 60 h of arrival. To allow for
adequate follow-up, subjects are excluded if the antici-
pated length of their hospital stay is less than 48 h, if
there is an existing documented intention to transfer
them to another hospital, or if the attending clinician be-
lieves the subject’s life expectancy is less than 3 months.
Intervention
The SENATOR software was designed by the project con-
sortium and implemented by the Clanwilliam Group®. It
produces a report, in the clinician’s native language, that
identifies potential risks, and opportunities for improve-
ment, in the participants’ current medication list. The
report has 5 components: [1] recommendations for modify-
ing or discontinuing a current medication; [2] recommen-
dations to initiate a new medication (both based on the
published STOPP/START guidelines); [3] identification of
major drug-drug and [4] drug-disease interactions (both
based on SafeScript®software and other local drug-drug and
drug-disease interaction databases) [5] and non-
pharmacological recommendations considered comple-
mentary to patients’ drug therapy. STOPP/START is a
widely used series of heuristic rules aimed at optimizing
drug prescribing in older patients [13], which has been
validated in a range of settings. SafeScript® is a validated
software system which uses the Summary of Product Char-
acteristics (SPCs) of ATC coded medications in conjunction
with ICD-10 coded conditions that was developed in the
UK [14]. The non-pharmacological recommendations in
the SENATOR report were based on the ‘Optimal
evidence-based Non-drug Therapies in Older People’
(ONTOP) programme [15]; these evidence-based recom-
mendations were developed independent of the trial as part
of the same FP7 funded project. Only the ONTOP recom-
mendations aimed at reducing the occurrence of incident
delirium were completed and available for inclusion in the
SENATOR report version used within the current trial.
Since all older subjects who are hospitalized are at risk for
developing delirium, the recommendations are provided to
all subjects randomized to the SENATOR intervention, ex-
cept those who already have delirium at the time of recruit-
ment. The ONTOP recommendations are included by way
of a demonstration of the potential utility of SENATOR as
a potential mechanism for promoting non-pharmacological
therapies i.e. as a proof of concept. However, the study was
not powered with the aim of estimating the benefits of the
ONTOP component.
In the intervention arm the participant’s clinical team
receive an individualized SENATOR report, at a single
time point within 60 h of hospital admission. Control
arm subjects and their doctors receive no additional
study specified intervention. All subjects have usual clin-
ical management whereby as part of routine care clini-
cians routinely review and adjust medications according
to their local practice. In addition, in one site the
Table 1 SENATOR Trial: Inclusion and exclusion criteria
Inclusion criteria
• ≥ 65 years
• Admitted with an acute illness under the care of a specialist other
than a geriatrician OR clinical pharmacologist OR palliative care
physician OR oncologist OR haematologist
• Consented into the study ≤60 h from time of arrival to the hospital
• Anticipated in hospital stay of > 48 h, in the opinion of the treating
physician
• ≥ 3 active (requiring current medication) chronic medical disorders
Exclusion criteria
• Elective hospitalisation
• Patients actively participating in another clinical trial of a medicinal
product
• Documented plan for consultation with Geriatric Medicine, Clinical
Pharmacology, Palliative Medicine, Clinical Oncology or
Haematology specialist services at the time of study recruitment
• Admission directly to an intensive care unit
• Primary acute psychiatric illness (excluding delirium)
• Admission with non-accidental overdose/self-harm
• Patients still under the care and responsibility of Emergency
Department Physicians
• Patients considered by the attending clinician to have a life
expectancy of < 3 months
• Anticipated immediate transfer to alternative non-participating
clinical service/hospital
• Receiving renal dialysis
• Clinical diagnosis of acute liver failure
• Solid organ transplant recipient
• Admitted to hospital > 60 h at time of attempted randomization.
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majority of hospitalized patients undergo a routine re-
view of their medications by a dedicated internal liaison
team or by a hospital pharmacist.
As SENATOR is a decision support tool, it efficiently
provides in a single report a range of evidence based rec-
ommendations, derived from general considerations.
Given the multiple complexities of clinical care, none of
these recommendations is mandated. Rather clinicians are
requested to review them in the context of the patient’s
unique clinical circumstances and to make any alterations
in accordance with the clinician’s best judgement.
Randomization
The patients are randomized into one of the two trial
arms with a 1:1 allocation ratio. Randomization is strati-
fied by study site and by admitting service type (i.e. med-
ical vs. surgical). The stratum-specific randomization
lists are generated using random block sizes by an inde-
pendent statistician.
Allocation concealment
Trial allocation is delivered using an interactive
Web-Response System developed in conjunction with
the main trial database by Clininfo®, the data manage-
ment partner company within the SENATOR project.
Subject allocation is released once all necessary baseline
information data have been entered into the trial data-
base and a decision is made to randomize. In subjects
randomized to the active intervention, trial data are
automatically transferred to the cloud based SENATOR
software engine maintained by Clanwilliam Health®, and
the resulting SENATOR report is automatically emailed
to the local trial research staff at a designated email.
Report dissemination
The local research team members place a printed copy
of the SENATOR report in the medical record or in the
case of two sites that exclusively use an electronic pa-
tient record, uploads it electronically. The researcher
further contacts a member of the clinical team and
emails the attending physician alerting him/her of the
report’s existence and requesting the attending physician
to review it and consider its recommendations. No
specific measures are applied to otherwise encourage or
oblige the clinician to adopt any of the report’s recom-
mendations. Given the nature of the intervention it is
not possible to effectively mask the intervention from
the clinical team or from the on-site researchers.
Trial administrative structures
The trial is coordinated by a dedicated Trial Coordin-
ation Committee based in the Health Research Board
(HRB) Clinical Research Facility at University College
Cork. A Trial Steering Committee, comprising of the
SENATOR grant work package leaders, meets regularly
by teleconference and supervises progress and commu-
nication including protocol amendments. An independ-
ent seven member Scientific Advisory Board meet
annually and review overall trial progress. The Scientific
Advisory Board members are all senior academic clini-
cians, including five geriatricians, one clinical pharma-
cologist and one pharmacist. An independent Ethics and
Data Safety Committee consisted of an academic geria-
trician, a senior hospital internal medicine physician
with an interest in ethics, a medical ethicist, and a pa-
tient advocate. The committee meets annually to review
trial metrics and any potential trial related deleterious
events. Trial Deleterious Events are also assessed by the
Trial coordinating Committee in real time.
Trial staff
The Trial Coordinating Committee is staffed by a dedicated
Trial Manager, an Endpoint Liaison Officer (both full time)
and a Data Manager, Biostatistician, and Trial Monitor
(part-time) who are supervised by the Trial Coordinating
Investigator. Each of the six sites is led by a site Principal
Investigator (PI), who is a senior physician specializing in
geriatric medicine and with extensive experience in geriatric
pharmacotherapy. These PIs oversee the recruitment, train-
ing and conduct of the local trial staff. All site staff are ICH
GCP certified researchers with medical, nursing or health
science backgrounds. Training consists of live interactive
tutorials, online ICD-10 training, case-based ADR adjudica-
tions, remote testing of the electronic case report form
(eCRF) at each clinical site, a central two day and subse-
quent one day meeting of all local site staff and web-based
site initiation visits prior to recruitment initiation. Audits
were performed by the Clinical Research Facility in Cork
(CRF-C) monitoring staff who were otherwise independent
of the running of the trial.
Data management
Although pragmatic and using a ‘real world’ approach to
the dissemination of the SENATOR report and with a vari-
able degree of engagement by the clinician, it has been ne-
cessary to develop and use a trial specific database to
gather the inputs used by the SENATOR software in a stan-
dardized fashion from the different countries and to collect
the trial outcome data which are collected to a far greater
degree of precision and accuracy than is usual in clinical
practise. To this end, data are entered electronically by the
local site research staff into a cloud based database devel-
oped by Clininfo®. Data collected is pseudo-anonymized
and includes baseline past medical history, current pre-
scription medications and doses, routine blood biochemis-
try and haematology laboratory data, baseline ECG data,
cognitive assessment using the Mini-Mental State Examin-
ation [16], functional assessment using the Barthel Index
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[17], and health related quality of life using the EQ-5D-5 L
[18]. At day 14 post randomization or at discharge, which-
ever occurs first, the EQ-5D-5 L is repeated, the subjects
medical conditions reviewed and medications recorded.
The case records are reviewed to assess the number of
SENATOR recommendations that have been adopted and
to identify any potential endpoints as discussed below. At
discharge arrangements are made with participants and/or
their family for a 12 weeks (+/− 4 weeks) post hospital dis-
charge follow-up call by the local site research staff. This is
to enquire about healthcare utilization and any
re-hospitalization since the index hospitalization, changes
in medications and current health related quality of life.
Trial endpoints
The Primary Endpoint is the proportion of patients with
at least one adjudicated probable or certain, non-trivial
incident in-hospital ADR occurring within 14 days of en-
rollment during the index hospitalization.
Secondary endpoints include
1. The proportion of patients with at least one
adjudicated possible, probable or certain, non-trivial
incident in-hospital ADR occurring within 14 days
of enrollment during index hospitalization.
2. The proportion of patients with at least one
adjudicated probable or certain, non-trivial hospital-
acquired, pre-specified (as per Table 2) ADR
occurring within 14 days of enrollment during index
hospitalization.
3. The number of adjudicated probable or certain,
non-trivial hospital-acquired ADRs occurring within
14 days of enrollment during the index
hospitalization (i.e. the count of Primary Endpoint
events).
4. The number of adjudicated possible, probable or
certain, non-trivial, incident, in-hospital ADR oc-
curring within 14 days of enrollment during index
hospitalization.
5. The number of adjudicated probable or certain,
non-trivial hospital-acquired, pre-specified (as per
Table 2), non-trivial, incident, in-hospital ADR oc-
curring within 14 days of enrollment during index
hospitalization.
Exploratory Endpoints include all-cause mortality dur-
ing index hospitalization; re-hospitalisation, composite
healthcare utilization, and health related quality of life at
12 weeks post-discharge follow-up; and utilization of
non-pharmacological interventions.
Patient safety
As the SENATOR Trial is not a regulated clinical trial
and is not intended for marketing authorization, and in
view of the proposed large recruitment of elderly
multi-morbid subjects, full pharmacovigilance reporting
of all adverse events will not be attempted. Clinicians
Table 2 Pre-specified event /ADR for which there is mandatory reporting of all events
Event Definition
Fall/s New fall/s
New onset unsteady gait New onset of unsteady gait that results in poor mobility and unsteady balance
Acute kidney injury An increase in serum creatinine by 0.3 mg/dl (26.5 μmol/l) within 48 h or an increase in serum creatinine by 1.5
baseline, which is known or presumed to have occurred within the prior 7 days
Symptomatic orthostatic
hypotension
A systolic blood pressure drop ≥20 mmHg ± diastolic blood pressure drop ≥10 mmHg within 3 min of standing
from the lying or sitting posture associated with symptoms
Major serum electrolyte
disturbance
A sodium (Na) of < 130mmol/l or > 145mmol/l and/or
a potassium (K+) < 3.5 mmol/l or > 5.2 mmol/l and/or
a corrected calcium (Ca++) < 2.1 mmol/l or > 2.7 mmol/l
Symptomatic bradycardia Heart rate of < 50 beats with symptoms
New major constipation Subjective symptoms of hard stools and/or less than 3 bowel movements per week and/or supported by nursing
records
Acute bleeding Malaena or haematuria or haematemesis or haemoptysis with or without a drop in haemoglobin level > 2 g/dl (not
due to rehydration) or associated symptoms (hypotension, tachycardia, pallor) or secondary renal failure
Acute dyspepsia/nausea/
vomiting
Subjective symptoms of acute ‘indigestion’/‘upset stomach’ or acute abdominal pain or acute refusal to eat or acute
heartburn/acid reflux or acute nausea/vomiting
Acute diarrhoea New liquid stools reported by the patient or the nursing staff or new liquid stools detected by medical staff on
physical examination or new liquid (non-solid) stools occurring more than 3 times in 24 h
Acute delirium Confirmed by a reliable witness and the DSM-V criteria. Supported by a 4AT≥ 4 and/or MMSE < 23/30
Symptomatic
hypoglycaemia
Symptoms with a blood glucose of < 3.5 mmol/L or < 63 mg/dl.
Unspecified adverse event For ADEs not specified above e.g. acute liver failure, anaphylaxis
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are encouraged to report any ADRs in accordance with
local clinical policies. Any protocol violation, participant
injury consequent to study involvement or related to the
application of SENATOR recommendations are reported
by the site researchers using a standardized ‘Deleterious
Event Form’ for review as appropriate by the Ethics
Committee(s), Trial Coordinating Centre, Coordinating
Investigator and the independent Ethics and Safety Re-
view Group.
Endpoint ascertainment
Potential ADRs are recorded by the site staff using dedi-
cated primary endpoint assessment forms based on a
retrospective review of all the available documentation
within the medical record, including medical, nursing
and allied health professional case note entries, labora-
tory values, radiology reports, electrocardiograms and
other investigations. The eligible period for endpoint oc-
currence extends from the day of randomization to the
time of index hospital discharge, or until 14 days post
randomization, whichever occurs first. In those subjects
whose discharge takes place after day 14 the medical
record is further reviewed at the time of discharge to de-
termine if any additional evidence from the subsequent
hospital course is relevant to the aetiology of a potential
study endpoint.
We identified the 12 most common types of ADRs which
represent approximately 80% of all hospital-acquired ADRs
in older multimorbid patients (Table 2). For each of these
pre-specified types of event, we developed a separate pri-
mary endpoint event-specific form, based on a standard
template as shown in Fig. 1, to allow for standardised ascer-
tainment of data relevant to that type of event. Any other
type of suspected ADRs is recorded using a generic primary
endpoint adverse event form. As several medications may
be implicated in the same event, the most likely culprit
medication, if identifiable, and any other potentially causal
or contributory medications implicated in the adverse event
are recorded. Generic evidence that supports causality such
as temporal relationship, dose response relationship, and
response to re-challenge, are recorded, along with any add-
itional qualifying explanatory text used by the local research
staff. The unblinded Site Investigator records whether the
ADR began prior to randomization (i.e. was prevalent and
therefore not part of the primary endpoint) or occurred
post-randomization, and his/her own assessment as to the
probability of the event being an ADR, and the severity of
the event. The strength of the available evidence supporting
the event being an ADR is ascertained using the
WHO-UMC ADR causality classification system [19],
which categorizes ADRs as certain, probable, possible, un-
likely or indeterminate. The severity of the event is classi-
fied using a modified Hartwig & Siegel scale [20], ranging
from trivial (event requires no specific investigation or
treatment and has no sequellae) to fatal.
While the recording of evidence supporting an ADR,
in a blinded fashion, using the relevant Potential End-
point Form facilitates the blinded assessment of possible
ADRs by the Adjudication Committee, it does not in
itself safeguard against the possibility of selective or dif-
ferential reporting of events to the Adjudication
Committee by local site staff. This is especially relevant
in the context of an open label trial, as the decision to
refer borderline events/possible ADRs is often highly
subjective. To avoid against the incomplete or differen-
tial submission of potential endpoints according to study
arm, we have mandated that all occurrences of the 12
pre-specified events as listed on Table 2 be reported
regardless of their presumed aetiology. Compliance with
this reporting approach is assessed by on-site
monitoring.
Given the difficulty with objectively and reliably
recording the number of separate discrete occurrences
of a specific type of ADR (e.g. episodes of diarrhoea), es-
pecially when using retrospective data review, we have
taken the approach of completing a single Potential End-
point Form for each type of ADR. This summarizes the
total available evidence that a particular drug played an
etiological role in the genesis of part or the totality of
the adverse event that may represent an ADR. Thus,
only one form is completed for each type of event re-
gardless of the number of possible discrete occurrences
of that particular adverse event during the index
hospitalization. A subject could experience several differ-
ent types of ADRs which are each recorded on their spe-
cific case report form or on the generic Potential
Endpoint Form, as appropriate.
ADR adjudication
The Potential Endpoint Form is sent electronically to
the blinded members of the Potential Endpoint Adjudi-
cation Committee, consisting of the six clinical Site Prin-
cipal Investigators. Each event is reviewed by up to five
Potential Endpoint Adjudication Committee members,
excluding members from the same site where the event
occurred. Each reviewer independently assesses the like-
lihood of the event being medication-related and the se-
verity of the event. An algorithm based on the
concordance of the independent assessments determines
the subsequent number of reviews required to obtain a
final decision on whether a non-trivial ADR has oc-
curred or not (Fig. 1). In brief, if the local site Principal
Investigator, upon unblinded review of the patient’s case
records and the Primary Endpoint Form, grades the
event as either ‘unlikely’ or ‘certain’ and the Endpoint Li-
aison Officer concurs, then the Evidence Form is
reviewed by a single blinded Endpoint Committee
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member (Stage 1). If the stage 1 Reviewer agrees with
the Site Principal Investigator, this decision is accepted
otherwise the form is reviewed by a second blinded End-
point Committee member as per Stage 2 below.
All Potential Endpoints judged by the unblinded
Site Principal Investigator to be possible, probable, or
indeterminate ADRs are directly reviewed independ-
ently by two committee members who are blinded to
the initial assessment (Stage 2). The adjudicated con-
clusion is determined by the Stage 2 Agreement
Matrix (Fig. 2); where reviewers agree, or any dis-
agreement is minor, an adjudicated result is assigned.
For more substantive levels of disagreement, the re-
view progresses to a 3rd blinded Endpoint Committee
member (Stage 3) and a majority consensus prevails
provided all 3 reviewers judge that the event is at
least a possible ADR. Otherwise the event is adjudi-
cated by consensus at a full committee meeting with
the Site Principal Investigator being recused.
Statistical methods
The intention-to-treat study population will consist of all
subjects who are randomized. The per-protocol popula-
tion will consist of those subjects who have at least 60% of
the SENATOR report STOPP recommendations acted on
by the clinical team. The safety population will include all
subjects who provide informed consent.
The primary analysis will compare the odds of subjects
in the SENATOR intervention and control groups ex-
periencing the primary endpoint as defined above using
Fig. 1 Potential Endpoint Adjudication Process
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a multiple logistic regression in the intention-to-treat
population, and adjusting for strata used in the
randomization (medical versus surgical admissions and
study recruitment site). The null hypothesis is that there
is no significant difference between control and SEN-
ATOR intervention groups in the adjusted odds of ex-
periencing the primary endpoint. The corresponding
estimated effect size will be reported as an odds ratio
(SENATOR: control) with 95% confidence intervals. Sec-
ondary endpoint analyses will use a similar approach.
The null hypothesis will be rejected if this confidence
interval excludes the null odds ratio of 1.0. Relevant in-
dividual and aggregate data on study related deleterious
events will be presented.
Sample size
In a recent single blinded trial of the manual application
of STOPP/START criteria, conducted at the coordinat-
ing investigator site, the observed control group
hospital-acquired ADR incidence was 21% compared to
an ADR incidence of 11.5% in the intervention group,
equivalent to an ADR odds-ratio of 0.45 [8]. This study
had similar entry criteria and primary endpoints to the
current trial, but differed in that the STOPP/ START
recommendations were manually generated and then
directly discussed and reviewed with the primary
team by a specialist registrar (senior resident) in geri-
atric medicine. To be conservative, and in view of the
more rigorous ADR adjudication processes, we have
based our power calculations for the current trial on
a lower control group event rate (18%) than that seen
in our earlier trial, and we assume a reduced effect
size (an odds ratio of 0.65) in order to reflect the po-
tential reduced uptake of recommendations by clini-
cians. Based on these assumptions, using the method
of Farrington and Manning for a trial to test the dif-
ference between two binomial events with a two-sided
type 1 error rate of 0.05, we achieve 90% power with
Fig. 2 ADR Stage 2 Adjudication Agreement Matrix
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the proposed recruitment of 900 subjects per trial
arm. The planned CONSORT flow diagram for the
trial is shown in Fig. 3.
Economic evaluation plan
The primary economic evaluation will present the
cost-effectiveness of the SENATOR intervention and
compare the costs with the primary endpoint of the
SENATOR intervention against usual care. A cost-utility
analysis (CUA) will also be undertaken to estimate the
costs and utilities as reported as quality-adjusted life
years (QALYs) over the 12-week follow-up period. The
incremental cost-effectiveness ratio (ICER) will therefore
present the cost per incremental ‘Quality Adjusted Life
Year’ of SENATOR in relation to standard management.
Costs for calculation will include medication use, in-
patient stay, further hospitalizations, hospital outpatient
visits (including physiotherapist, OT), and community-
based or health/social care visits. Resource use will be
calculated according to the average unit cost of inpatient,
outpatient and community visits across sites. In light of the
intervention having no clear explicit cost/price, deployment
costs of the SENATOR tool from an end-users’ perspective
will be estimated by means of a brief user-survey.
The outcomes will be estimated as utilities, as reported
from EQ-5D-3 L [18] eCRF data at baseline, day 14 or
discharge, and 12-week follow up. The difference in
QALY score between the two arms will be estimated
using the “area under the curve” method.
The analysis will be undertaken from a payer perspec-
tive. Appropriate sensitivity and statistical analysis will
be undertaken to test the uncertainty of the effect on the
cost and QALY effect.
Discussion
With a progressive global shortage of specialist geriatri-
cians to treat the rapidly growing frailer multi-morbid
Fig. 3 Consort Flow Diagram depicting the SENATOR clinical trial organization
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older population, pragmatic cost-effective strategies to
improve pharmacotherapy for older adults are urgently
needed. The majority of drug prescriptions for older
multi-morbid people currently and in the future will eman-
ate from clinicians who are neither specialist geriatricians
nor clinical pharmacologists. Strategies to optimise the
pharmacotherapy of older multi-morbid people and simul-
taneously minimize drug-related harm must be devised and
tested. Previous studies have shown that the implementa-
tion of medication reconciliation [21] and comprehensive
geriatric assessment [22] reduce inappropriate prescribing
and potentially ADRs, but both these approaches are time
consuming, expensive and require experienced clinical staff.
The SENATOR software has the capability of highlighting
the most common potentially inappropriate prescriptions
to a non-specialist clinician in an efficient manner and in
so doing prompt alterations which will reduce risks of inci-
dent ADRs. If successful this will result in older patients
suffering fewer adverse medication-related outcomes with
associated economic benefits.
Prior to finalizing the trial protocol we conducted a
non-interventional feasibility study at the same sites that
are participating in the trial [23]. The feasibility study
highlighted several challenges that led us to modify our
initial trial design and our approach to the assessment of
ADRs in the current trial.
We had initially proposed a cluster randomized trial
adjusting for difference in baseline ADR risk using an
ADR prediction tool such as the previously validated
Gerontonet ADR Risk Scale [6]. This approach had the
specific advantage of limiting contamination between
the intervention and control arm, especially if it transpired
that the same investigator was simultaneously attending a
subject in both arms of the trial. However, in our feasibil-
ity study we discovered a very large degree of heterogen-
eity in ADR rates between different sites and between
specialities within individual sites. Some of this heterogen-
eity may have resulted from initial limited standardization
of our ADR reporting and adjudication processes and
from sampling variability given the limited sizes of in-
dividual samples as well as real substantive differences
between sites. Furthermore, we found that within our
population the ADR predictions tools were inadequate
for correcting for the between-cluster variability in
baseline ADR risk. This made it impossible to exclude
the possibility that any observed differences in the
proposed trial might not simply be the consequence
of an unequal distribution of baseline ADR risks
across sites. We therefore adopted an individual level
randomization, accepting that a degree of cross arm
contamination might dilute the perceived effect size.
However, even in a cluster design this effect is not
fully prevented because junior medical staff routinely
migrate between various specialities within a hospital
and senior clinicians typically cross cover other spe-
cialist services at weekends and when working on-call
outside of regular daytime hours.
The assessment of ADRs gives rise to several methodo-
logical complexities that have not previously been widely
discussed in the literature. It is necessary to distinguish
between prevalent (pre-dating the hospitalization and on
occasion necessitating it) and incident ADRs, which occur
during the index hospital stay. These are likely to differ in
their characteristics, risk factors and consequences, making
the distinction particularly relevant for ADR risk prediction
tools. From the SENATOR trial viewpoint, it is necessary to
exclude ADRs occurring prior to randomization; therefore
outcomes in this trial will only include in-hospital incident
ADRs that occur post randomization, but we also take ac-
count of whether identification and response to prevalent
ADRs is influenced by study intervention.
The feasibility study highlighted the difficulty in reliably
separating prolonged or repeated occurrences of the same
ADR into separate discrete events in a reproducible fashion.
This would necessitate defining a minimal interval between
events and requires more detailed information on the tim-
ing of events than is usually present in clinical records or at
least amenable to retrospective assessment. We therefore
conceptualized ADRs as processes which are predisposed
by one or more medications. This uses a patient-specific ra-
ther than a medication-specific perspective, therefore an
ADR with two different potential implicated medications at
different times is still considered a single potential
endpoint. This potential loss of precision in defining ADRs
is necessary for reproducibility and avoidance of an unduly
subjective determination of the number of discrete
episodes.
We adopted a retrospective approach to ADR assessment
for two reasons. Firstly, real time assessment could poten-
tially influence attending clinician or patient behaviour in-
dependently of the intervention. Secondly, there is the need
to avoid situations where the site researcher identifies a po-
tentially dangerous inappropriate prescribing in real time,
leading to an ethical dilemma of whether or not to alert the
attending clinical staff, thereby potentially distorting trial
data. While a retrospective assessment may result in some
ADRs not being clearly identified, our contention is that an
adverse event that does not leave any evidence in the med-
ical notes, nursing notes or elsewhere in the case records in
the highly monitored hospital environment is more likely
to be trivial in nature.
In keeping with the open label design that is unavoid-
able in a trial of a decision support tool and in view of
the somewhat subjective nature of ADR ascertainment,
it is necessary to use a detailed process to allow for
blinded potential end-point adjudication. We optimized
the function of this process by the use of an algorithm
that varies the number of required potential end-point
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reviews depending on the degree of concordance be-
tween blinded reviewers and the strength of the initial
reviewers’ assessment. We have also considered carefully
the definitions used in our outcomes. Thus, the distinc-
tion between ‘certain’ and ‘probable’ ADR is less relevant
as both are primary endpoints in contrast to the distinc-
tion between ‘possible’ and ‘probable’ ADR and between
‘possible’ and ‘unlikely’ ADR which have more influence
on the secondary outcomes.
SENATOR is a complex clinical trial with many chal-
lenges. For this trial to succeed, attending clinicians in
the intervention arm need to implement the recommen-
dations of the SENATOR report. To date, adherence
with software-generated prescribing advice in other
studies has been highly variable [24]. In addition, ADRs
need to be recorded and adjudicated in a comprehensive
and unbiased fashion. SENATOR is the first
multi-national randomized trial in which a prescribing
optimization software specially designed to minimize
ADRs and potential prescribing omissions will be tested
on a large scale. If the SENATOR trial shows the soft-
ware to be effective for minimizing ADRs and their con-
sequences, there is the potential for routine prescribing
optimization for large numbers of multi-morbid older
people that is software-driven. A critical question that
this trial will address is the extent to which the prescrib-
ing advice provided in the software-generated SEN-
ATOR report will be considered appropriate by busy
clinicians and applied accordingly to their patients’ pre-
scriptions in the acute hospital setting.
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